Mycosis Fungoides disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MYC006 MIFTS: 65	Mycosis Fungoides Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Mycosis Fungoides

MalaCards integrated aliases for Mycosis Fungoides:

Name: Mycosis Fungoides ⁵⁷ ¹¹ ¹⁹ ⁴² ⁷⁵ ⁵³ ⁴³ ¹⁴ ³⁶ ¹⁶ ⁷¹ ³¹ ³³

Mycosis Fungoides Lymphoma ¹¹ ⁷⁵

Alibert-Bazin Syndrome ¹⁹ ⁴²

Granuloma Fungoides ¹⁹ ⁴²

Mycosis Fungoides, Alibert-Bazin Type ⁵⁸

Classic Mycosis Fungoides ⁵⁸

Characteristics:

Inheritance:

Mycosis Fungoides: Familial aggregation without simple mendelian pattern ⁵⁷

Classic Mycosis Fungoides: Multigenic/multifactorial ⁵⁸

Prevelance:

Classic Mycosis Fungoides: 1-9/1000000 (Europe) ⁵⁸

Age Of Onset:

Classic Mycosis Fungoides: Adult ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Skin diseases Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Mature T/NK-cell lymphomas

Mycosis fungoides

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature T-cell or NK-cell neoplasms

Mature T-cell or NK-cell lymphomas and lymphoproliferative disorders, primary cutaneous specified types

Mycosis fungoides

Orphanet: ⁵⁸

Rare skin diseases

Rare haematological diseases

Sources

Summaries for Mycosis Fungoides

MedlinePlus Genetics: ⁴² Mycosis fungoides is the most common form of a type of blood cancer called cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers characteristically affect the skin, causing different types of skin lesions. Although the skin is involved, the skin cells themselves are not cancerous. Mycosis fungoides usually occurs in adults over age 50, although affected children have been identified.Mycosis fungoides may progress slowly through several stages, although not all people with the condition progress through all stages. Most affected individuals initially develop skin lesions called patches, which are flat, scaly, pink or red areas on the skin that can be itchy. Cancerous T cells, which cause the formation of patches, are found in these lesions. The skin cells themselves are not cancerous; the skin problems result when cancerous T cells move from the blood into the skin. Patches are most commonly found on the lower abdomen, upper thighs, buttocks, and breasts. They can disappear and reappear or remain stable over time. In some affected individuals, patches progress to plaques, the next stage of mycosis fungoides.Plaques are raised lesions that are usually reddish, purplish, or brownish in color and itchy. Plaques commonly occur in the same body regions as patches. While some plaques arise from patches, others develop on their own, and an affected person can have both patches and plaques simultaneously. As with patches, cancerous T cells are found in plaques. Plaques can remain stable or can develop into tumors. Not everyone with patches or plaques develops tumors.The tumors in mycosis fungoides, which are composed of cancerous T cells, are raised nodules that are thicker and deeper than plaques. They can arise from patches or plaques or occur on their own. Mycosis fungoides was so named because the tumors can resemble mushrooms, a type of fungus. Common locations for tumor development include the upper thighs and groin, breasts, armpits, and the crook of the elbow. Open sores may develop on the tumors, often leading to infection.Although rare, the cancerous T cells can spread to other organs, including the lymph nodes, spleen, liver, and lungs. Spread to other organs can occur in any stage of mycosis fungoides but is most common in the tumor stage. In addition, affected individuals have an increased risk of developing another lymphoma or other type of cancer.

MalaCards based summary: Mycosis Fungoides, also known as mycosis fungoides lymphoma, is related to lymphoproliferative syndrome, x-linked, 1 and lymphoma. An important gene associated with Mycosis Fungoides is CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4), and among its related pathways/superpathways are Innate Immune System and Signal Transduction. The drugs Denileukin diftitox and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and bone marrow, and related phenotypes are dry skin and neoplasm of the skin

OMIM®: ⁵⁷ Mycosis fungoides is a malignant T-cell lymphoma of the skin, first reported (and named) by Alibert (1835). Sezary syndrome is a leukemic variant of mycosis fungoides defined by erythroderma with greater than 80% of the skin showing redness, adenopathy and greater than 1,000 circulating Sezary cells/microliter with a CD4+CD26- or CD4+CD7- phenotype. Sezary cells have a type 2 helper T cell cytokine profile. Sezary syndrome has a median overall survival time of only 2.4 years in patients with Sezary cells at a density of greater than 10,000 cells/microliter or 5.4 years in patients with 1,000-10,000 Sezary cells/microliter. Mycosis fungoides and Sezary syndrome are the most common cutaneous T-cell lymphomas. Sezary syndrome can arise de novo or can appear following years of chronic mycosis fungoides. Both are thought to arise from clonal expansion of CD4+ helper T cells responding to chronic antigen stimulation (summary by Wang et al., 2015). (254400) (Updated 08-Dec-2022)

GARD: ¹⁹ Mycosis fungoides is a disease in which T-cell lymphocytes (a type of white blood cell) become malignant (cancerous) and affect the skin. This condition is one of the most common types of T-cell lymphoma. Mycosis fungoides is characterized by a scaly, red rash that develops on the skin, particularly on areas that are not usually exposed to the sun. Over time, a thin, reddened, eczema-like rash may develop, followed by thickened, red patches of skin.

Orphanet: ⁵⁸ Classical mycosis fungoides is the most common type of mycosis fungoides (MF; see this term), a form of cutaneous T-cell lymphoma, and is characterized by slow progression from patches to more infiltrated plaques and eventually to tumors.

Wikipedia: ⁷⁵ Mycosis fungoides, also known as Alibert-Bazin syndrome or granuloma fungoides, is the most common form... more...

Sources

Related Diseases for Mycosis Fungoides

Diseases related to Mycosis Fungoides via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoproliferative syndrome, x-linked, 1	32.6	TNFRSF8 TIA1 CXCR3 CCR4
2	lymphoma	32.2	TNFRSF8 TIA1 STAT3 IL2RA IL2 CDKN2B
3	parapsoriasis	32.1	TNFRSF8 CD7
4	primary cutaneous t-cell non-hodgkin lymphoma	32.0	TNFRSF8 TIA1 STAT3 ITGAE IL2RA IL2
5	follicular mucinosis	31.9	TNFRSF8 TIA1 CD7
6	burkitt lymphoma	31.8	TNFRSF8 STAT3 IFNA1 CDKN2B
7	sezary's disease	31.8	TNFRSF8 TNFRSF1B TIA1 STAT3 IL2RA IL2
8	lymphoproliferative syndrome	31.7	TNFRSF8 TIA1 STAT3 IL2 CTLA4
9	exanthem	31.6	IL2 IFNA1 CTLA4
10	anaplastic large cell lymphoma	31.6	TNFRSF8 STAT3 IL2RA CXCR3 CCR4 CCL17
11	dermatitis	31.6	STAT3 IL2 CXCR3 CXCL9 CTLA4 CCR4
12	contact dermatitis	31.6	IL2 CXCR3 CXCL9 CCR4 CCL22 CCL17
13	b-cell lymphoma	31.6	TNFRSF8 TIA1 STAT3 CXCR3 CDKN2B
14	hypereosinophilic syndrome	31.4	STAT3 IL2RA IL2 IFNA2 IFNA1 CCL17
15	lymphoma, hodgkin, classic	31.4	TNFRSF8 TIA1 STAT3 IL2RA IL2 CD28
16	lichen planus	31.4	IL2 CXCR3 CXCL9
17	adult t-cell leukemia/lymphoma	31.4	TNFRSF8 IL2RA IL2 CTLA4 CD7 CCR4
18	t-cell acute lymphoblastic leukemia	31.4	TNFRSF8 STAT3 IL2RA IL2 CD7 CD28
19	peripheral t-cell lymphoma	31.3	TNFRSF8 TIA1 STAT3 IL2RA CXCR3 CD7
20	herpes zoster	31.3	IL2 IFNA2 IFNA1
21	dermatitis, atopic	31.3	TNFRSF8 STAT3 IL2RA IL2 CXCR3 CXCL9
22	alopecia areata	31.3	IL2RA IL2 CXCR3 CXCL9 CTLA4
23	allergic contact dermatitis	31.2	IL2 CXCR3 CXCL9 CCR4 CCL22 CCL17
24	spongiotic dermatitis	31.2	TNFRSF8 CD7
25	lymphoma, non-hodgkin, familial	31.2	TNFRSF8 STAT3 IL2RA IL2 CTLA4 CDKN2B
26	allergic disease	31.2	IL2 CD28 CCL22 CCL17
27	lymphopenia	31.2	IL2RA IL2 CTLA4 CCL22
28	angioimmunoblastic t-cell lymphoma	31.1	TNFRSF8 TIA1 CD7
29	t-cell adult acute lymphocytic leukemia	31.1	TNFRSF8 TIA1 IL2 CD7 CCR4
30	sarcoidosis 1	31.1	TNFRSF1B IL2RA IL2 CXCR3 CXCL9 CD28
31	melanoma	31.1	STAT3 IL2 IFNA2 IFNA1 CXCR3 CTLA4
32	nasal type extranodal nk/t-cell lymphoma	31.1	TNFRSF8 TIA1
33	psoriasis	30.9	TNFRSF1B STAT3 IL2RA IL2 DPP4 CXCR3
34	skin disease	30.9	TNFRSF8 STAT3 ITGAE IL2 IFNA1 DPP4
35	skin sarcoidosis	30.9	IL2 IFNA1 CTLA4
36	uveitis	30.9	IL2RA IL2 IFNA2 CXCR3 CTLA4
37	acute graft versus host disease	30.9	IL2RA IL2
38	leukemia, chronic myeloid	30.8	STAT3 IL2 IFNA2 IFNA1 CTLA4 CDKN2B
39	diphtheria	30.8	IL2RA IL2 IFNA1
40	peripheral nervous system disease	30.8	TNFRSF8 STAT3 IL2 IFNA1 DPP4 CTLA4
41	mature t-cell and nk-cell lymphoma	30.8	TNFRSF8 TIA1 STAT3 IL2 CTLA4 CD7
42	lymphoblastic lymphoma	30.8	TNFRSF8 CDKN2B CD7
43	leukemia, chronic lymphocytic	30.8	TNFRSF8 STAT3 ITGAE IL2RA IL2 IFNA1
44	thrombocytopenia	30.7	STAT3 IL2 IFNA2 IFNA1 CTLA4 CDKN2B
45	chickenpox	30.7	IL2 IFNA1 CTLA4
46	hairy cell leukemia	30.7	ITGAE IL2RA IL2 IFNA2 IFNA1
47	leukemia, acute lymphoblastic	30.7	IL2 CXCR3 CTLA4 CDKN2B CD7 CD28
48	lymphadenitis	30.7	IL2RA CXCR3 CXCL9 CCL22
49	primary cutaneous gamma-delta t-cell lymphoma	30.7	TNFRSF8 TIA1 CD7
50	lymphomatoid granulomatosis	30.6	TIA1 IFNA2 IFNA1 CXCL9

Graphical network of the top 20 diseases related to Mycosis Fungoides:

Sources

Symptoms & Phenotypes for Mycosis Fungoides

Human phenotypes related to Mycosis Fungoides:

⁵⁸ ³⁰ (show all 24)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	dry skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000958
2	neoplasm of the skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0008069
3	erythema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0010783
4	skin rash ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000988
5	eczema ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000964
6	pruritus ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0000989
7	skin plaque ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0200035
8	abnormal lymphocyte morphology ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0004332
9	alopecia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001596
10	hypopigmented skin patches ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001053
11	irregular hyperpigmentation ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0007400
12	lymphadenopathy ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002716
13	poikiloderma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0001029
14	cutaneous t-cell lymphoma ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012192
15	splenomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001744
16	hepatomegaly ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002240
17	abnormality of the nail ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001597
18	hyperkeratosis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000962
19	skin ulcer ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0200042
20	abnormal eyelid morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000492
21	abnormality of bone marrow cell morphology ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0005561
22	edema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000969
23	lymphoma ⁵⁸ ³⁰		Very frequent (99-80%)	HP:0002665
24	psoriasiform dermatitis ³⁰			HP:0003765

Symptoms via clinical synopsis from OMIM®:

⁵⁷ (Updated 08-Dec-2022)

Skin Nails Hair Skin:
erythema
pruritus
psoriasiform dermatitis
malignant t-cell skin lymphoma
skin scaling
more

Immunology:
lymphadenopathy

Clinical features from OMIM®:

254400 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.14	CCL17 CCL22 CCR10 CCR4 CD28 CD7
2	no effect	GR00402-S-2	10.14	CCL22 CCR10 CCR4 CD28 CD7 CDKN2B

MGI Mouse Phenotypes related to Mycosis Fungoides:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	10.16	CCL17 CCL22 CCR10 CCR4 CD28 CD7
2	endocrine/exocrine gland	MP:0005379	10	CCR10 CD28 CD7 CDKN2B CTLA4 DPP4
3	respiratory system	MP:0005388	9.65	CCR4 CTLA4 CXCR3 DPP4 IFNA1 IFNA2
4	hematopoietic system	MP:0005397	9.6	CCL17 CCR10 CCR4 CD28 CD7 CDKN2B

Sources

Drugs & Therapeutics for Mycosis Fungoides

Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 218)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Denileukin diftitox

Approved, Investigational

Phase 4

173146-27-5

Levoleucovorin

Approved, Experimental, Investigational

Phase 4

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 4

1959-05-2, 59-05-2

4112 126941

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 4

59-30-3

6037

Pharmaceutical Solutions

Phase 4

interferons

Phase 4

Folic Acid Antagonists

Phase 4

Folate

Phase 4

Vitamin B9

Phase 4

Vitamin B Complex

Phase 4

Interferon alpha-2

Phase 4

Interferon-alpha

Phase 4

Clorazepate Dipotassium

Phase 4

Brentuximab vedotin

Approved, Investigational

Phase 3

914088-09-8

Bexarotene

Approved, Investigational

Phase 3

153559-49-0

82146

Naloxone

Approved, Vet_approved

Phase 3

465-65-6

5284596

Hypericin

Investigational

Phase 3

548-04-9

5281051

Zanolimumab

Investigational

Phase 3

652153-01-0

Antiviral Agents

Phase 3

Anti-Infective Agents

Phase 3

Immunosuppressive Agents

Phase 3

Immunologic Factors

Phase 3

Dermatologic Agents

Phase 3

Furocoumarins

Phase 3

Psychotropic Drugs

Phase 3

Antidepressive Agents

Phase 3

Antineoplastic Agents, Immunological

Phase 3

Immunoglobulins

Phase 3

Antibodies

Phase 3

Antibodies, Monoclonal

Phase 3

Opiate Alkaloids

Phase 3

Narcotic Antagonists

Phase 3

Narcotics

Phase 3

Miconazole

Approved, Investigational, Vet_approved

Phase 2

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 2

23593-75-1

2812

Carboplatin

Approved

Phase 1, Phase 2

41575-94-4

10339178 38904

Alemtuzumab

Approved, Investigational

Phase 2

216503-57-0

Petrolatum

Approved, Investigational

Phase 2

8009-03-8

Ondansetron

Approved, Withdrawn

Phase 2

99614-02-5

4595

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Prednisolone phosphate

Approved, Vet_approved

Phase 2

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 2

52-21-1

Prednisolone

Approved, Vet_approved

Phase 2

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 2

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 2

83-43-2

4159 6741

Rosiglitazone

Approved, Investigational

Phase 2

122320-73-4, 155141-29-0

77999

Panobinostat

Approved, Investigational

Phase 1, Phase 2

404950-80-7

6918837

Everolimus

Approved

Phase 1, Phase 2

159351-69-6

70789204 6442177

Interventional clinical trials:

(show top 50) (show all 213)

#	Name	Status	NCT ID	Phase	Drugs
1	UVADEX Sterile Solution in Conjunction With the UVAR XTS Photopheresis System as an Interventional Therapy for the Treatment Of CTCL (Mycosis Fungoides) in Patients With TMN Classification Stage 1A, 1B, 2A	Completed	NCT00221039	Phase 4	Methoxsalen+ECP
2	A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25	Completed	NCT00051012	Phase 4	ONTAK
3	A Multicenter Phase III Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy of Two Dose Levels of DAB389IL-2 (9 and 18 Mcg/kg/Day) in Cutaneous T-Cell Lymphoma (CTCL) Patients With Stage Ia-III Disease Who, Following Less Than or Equal to 3 Previous Therapies, Have Recurrent or Persistent Disease That Has Been Biopsy-Documented to Express CD25	Completed	NCT00050999	Phase 4	ONTAK
4	Prospective, Randomized Multicentic to Compare PUVA+IFN Alpha 2a vs PUVA Alone in Mycosis Fungoides Stages Ia, Ib or IIa.	Terminated	NCT00630903	Phase 4	PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA)
5	Comparison of Methotrexate Versus Interferon-alfa 2b on Efficacy, Safety and Quality of Life in Patients With Primary Cutaneous T-cell Lymphomas	Terminated	NCT02323659	Phase 4	Methotrexate;Interferon Alfa-2b
6	Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides: A Randomized Controlled Trial	Unknown status	NCT03454945	Phase 3	Vibramycin
7	A Multi-center, Randomized Study on Oral 8-methoxypsoralen Plus UVA With or Without Maintenance Therapy in Mycosis Fungoides EORTC/ISCL Stage IA to IIB	Completed	NCT01686594	Phase 3	8-methoxypsoralen
8	A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma	Completed	NCT01578499	Phase 3	Brentuximab Vedotin;Methotrexate;Bexarotene
9	A Phase 3 Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Determine the Efficacy of Topical SGX301 (Synthetic Hypericin) and Fluorescent Bulb-Light Irradiation for the Treatment of Cutaneous T-Cell Lymphoma	Completed	NCT02448381	Phase 3	SGX301 (synthetic hypericin);Placebo
10	TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides: a Prospective Randomized Controlled Study	Not yet recruiting	NCT05205902	Phase 3
11	Open Label, Dose Escalation, Followed by Open Label,Single Arm Clinical Trial of HuMax-CD4 in Patients With Mycosis Fungoides Type CTCL (Stage IB-IVB) or Sezary Syndrome Who Are Refractory or Intolerant to Targretin® (Bexarotene) and One Other Standard Therapy	Terminated	NCT00127881	Phase 3	HuMax-CD4 (zanolimumab)
12	A Randomized, Open-Label Phase III Trial to Evaluate the Efficacy and Safety of Bexarotene (Targretin) Capsules Combined With PUVA, Compared to PUVA Treatment Alone in Patients With Mycosis Fungoides	Terminated	NCT00056056	Phase 3	bexarotene;methoxypsoralen
13	A Double Blind Randomized Vehicle Controlled Crossover Study to Evaluate the Safety and Efficacy of Topical Naloxone Hydrochloride Lotion 0.5% for the Relief of Pruritus in Patients With the MF or SS Forms of Cutaneous T-Cell Lymphoma	Terminated	NCT02811783	Phase 3	Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion
14	A Phase I/II Study of Pembrolizumab (MK-3475) in Combination With Romidepsin in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma	Unknown status	NCT03278782	Phase 1, Phase 2	Romidepsin
15	PROTOCOL FOR THE MANAGEMENT OF MYCOSIS FUNGOIDES AND THE SEZARY SYNDROME	Unknown status	NCT00002557	Phase 2	CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate
16	Phase II Study of Alemtuzumab in Patients With Advanced Mycosis Fungoides/Sezary Syndrome	Unknown status	NCT00157274	Phase 2	alemtuzumab
17	Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial	Unknown status	NCT02943642	Phase 2	Vorinostat
18	Phase II Study of Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides	Unknown status	NCT02881749	Phase 2	mechlorethamine gel 0.016%
19	A Single Arm, Open-Label Study To Evaluate The Safety, Tolerability And Preliminary Efficacy Of NM-IL-12 (rHuIL-12) In Patients With Cutaneous T Cell Lymphoma (CTCL) Undergoing Low Dose Total Skin Electron Beam Therapy (TSEBT)	Unknown status	NCT02542124	Phase 2
20	A Phase 2 Study of MK-3475 for the Treatment of Relapsed/Refractory Mycosis Fungoides/Sezary Syndrome	Completed	NCT02243579	Phase 2
21	A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil	Completed	NCT00089011	Phase 2	fludarabine phosphate;mycophenolate mofetil;tacrolimus
22	A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens	Completed	NCT00489203	Phase 2	beclomethasone dipropionate;placebo;tacrolimus;methotrexate
23	Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study)	Completed	NCT03380026	Phase 2	Triamcinolone;Valchlor 0.016 % Topical Gel
24	A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma	Completed	NCT00601718	Phase 1, Phase 2	vorinostat;ifosfamide;carboplatin;etoposide
25	A Phase II Study of 506U78 in Patients With Previously Systemically Untreated Cutaneous T-cell Lymphoma (CTCL) or With Refractory or Relapsed Non-cutaneous Peripheral T-cell Lymphoma (PTCL)	Completed	NCT00005080	Phase 2	nelarabine
26	Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial	Completed	NCT00040846	Phase 2	fludarabine phosphate;mycophenolate mofetil;cyclosporine
27	Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload	Completed	NCT01273766	Phase 2	deferasirox
28	Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation	Completed	NCT00049504	Phase 2	cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
29	A Phase I/II Multicenter Clinical Trial of O6Benzylguanine and Topical Carmustine in the Treatment of Refractory Early-Stage (IA-IIA) Cutaneous T-Cell Lymphoma	Completed	NCT00961220	Phase 1, Phase 2	Carmustine;O6-Benzylguanine
30	An Open Label Study to Evaluate the Safety and Efficacy of Nitrogen Mustard (Mechlorethamine - MCH) 0.04% Formulation in Patients With Stage I-IIA Mycosis Fungoides Who Have Completed 12 Months Treatment Without a Complete Response	Completed	NCT00535470	Phase 2	0.04% Mechlorethamine gel
31	A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)	Completed	NCT00168064	Phase 2	mechlorethamine-MCH (nitrogen mustard)
32	A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis	Completed	NCT00099255	Phase 2	SGN-30
33	A Phase I/II Study of HLA-matched Mobilized Peripheral Blood Hematopoietic Stem Cell Transplantation for Advanced Mycosis Fungoides/Sezary Syndrome Using Nonmyeloablative Conditioning With Campath-1H	Completed	NCT00047060	Phase 1, Phase 2	cyclosporine;fludarabine;Campath
34	A Phase II Study of Total Skin Electron Beam Therapy (TSEBT) to Dose of 12 Gy in Stage IB-IIIA Mycosis Fungoides	Completed	NCT01073267	Phase 2
35	Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy	Completed	NCT00074087	Phase 2	pegylated liposomal doxorubicin hydrochloride
36	Phase II Trial Of Campath-1H In Patients With Relapsed/Refractory Advanced Mycosis Fungoides or Sezary Syndrome	Completed	NCT00057967	Phase 2
37	Phase II Trial of Tretinoin (TRA) in Patients With Mycosis Fungoides/Sezary Syndrome	Completed	NCT00002479	Phase 2	tretinoin
38	Exploratory Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level	Completed	NCT01396070	Phase 2	Brentuximab vedotin
39	Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies	Completed	NCT01839916	Phase 2
40	Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells	Completed	NCT00795769	Phase 2	ondansetron
41	Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial	Completed	NCT00078858	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
42	A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED)	Completed	NCT01110135	Phase 2	bendamustine hydrochloride;dexamethasone;etoposide
43	Phase II Study of Interferon Alpha and Isotretinoin in Patients With T-Cell Malignancies	Completed	NCT00038376	Phase 2	Isotretinoin (Accutane);Interferon Alpha
44	Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil	Completed	NCT00006251	Phase 1, Phase 2	fludarabine phosphate;cyclosporine;mycophenolate mofetil
45	Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies	Completed	NCT01093586	Phase 2	busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
46	Le23 CPG: A Phase 1-2 Study of Intratumoral Injection of CPG 7909, A TLR 9 Agonist, Combined With Local Radiation in Recurrent Low-Grade Lymphomas	Completed	NCT00185965	Phase 1, Phase 2	CPG 7909
47	Open Label Pilot Study of Combination Therapy With Rosiglitazone and Bexarotene to Investigate a Possible Synergism in the Treatment of Cutaneous T-Cell Lymphoma	Completed	NCT00178841	Phase 2	Rosiglitazone and Bexarotene
48	Phase IIb Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-cell Lymphoma	Completed	NCT00091559	Phase 2	MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months
49	A Phase I/II Study of the Histone Deacetylase (HDAC) Inhibitor LBH589 (Panobinostat) in Combination With mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Multiple Myeloma or Lymphoma	Completed	NCT00918333	Phase 1, Phase 2	panobinostat;everolimus
50	A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma	Completed	NCT00611208	Phase 2

Search NIH Clinical Center for Mycosis Fungoides

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cyclophosphamide

Etoposide

etoposide phosphate

Interferon Alfa-2a

Interferon Alfa-2b

INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED

interferon alfacon-1

Interferon gamma-1b

Interferons

Mechlorethamine

Mechlorethamine hydrochloride

Methotrexate

Methotrexate Sodium

Methoxsalen

peginterferon alfa-2a

peginterferon alfa-2b

Recombinant interferon beta-1a

Recombinant interferon beta-1b

Uracil Mustard

Vinblastine

Vinblastine Sulfate

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Mycosis Fungoides cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Mycosis Fungoides:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies

Embryonic/Adult Cultured Cells Related to Mycosis Fungoides:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: mycosis fungoides

Sources

Genetic Tests for Mycosis Fungoides

Sources

Anatomical Context for Mycosis Fungoides

Organs/tissues related to Mycosis Fungoides:

MalaCards : Skin, T Cells, Bone Marrow, Liver, Spleen, Bone, Myeloid

Sources

Publications for Mycosis Fungoides

Articles related to Mycosis Fungoides:

(show top 50) (show all 6723)

#	Title	Authors	PMID	Year
1	Lymphomas and leukemias in the relatives of patients with mycosis fungoides. ⁶² ⁵⁷	Greene MH...Dalager NA	7055783	1982
2	Familial mycosis fungoides revisited. ⁶² ⁵⁷	Shelley WB	7425665	1980
3	Mycosis fungoides of prolonged duration in siblings. ⁶² ⁵⁷	Sandbank M...Katzenellenbogen I	5246760	1968
4	Genomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genes. ⁵⁷	Wang L...Duvic M	26551670	2015
5	The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome. ⁵⁷	da Silva Almeida AC...Palomero T	26551667	2015
6	Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. ⁵³ ⁶²	Prince HM...Negro-Vilar A	20212249	2010
7	Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors. ⁵³ ⁶²	Wu XS...Hwang ST	19242508	2009
8	Clusterin expression correlates with stage and presence of large cells in mycosis fungoides. ⁵³ ⁶²	Chandra P...Prieto VG	19289586	2009
9	Clusterin expression in cutaneous CD30-positive lymphoproliferative disorders and their histologic simulants. ⁵³ ⁶²	Olsen SH...Fullen DR	19220628	2009
10	Lesional skin chemokine CTACK/CCL27 expression in mycosis fungoides and disease control by IFN-alpha and PUVA therapy. ⁵³ ⁶²	Goteri G...Leoni P	19956431	2009
11	Differential CCR4 expression and function in cutaneous T-cell lymphoma cell lines. ⁵³ ⁶²	Wu CS...Wu MT	19239991	2008
12	The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. ⁵³ ⁶²	Massone C...Cerroni L	18644018	2008
13	The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. ⁵³ ⁶²	Kelemen K...Peterson LC	18089499	2008
14	Defucosylated anti CC chemokine receptor 4 monoclonal antibody combined with immunomodulatory cytokines: a novel immunotherapy for aggressive/refractory Mycosis fungoides and Sezary syndrome. ⁵³ ⁶²	Yano H...Ueda R	17975162	2007
15	Phase II trial of subcutaneous injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sézary syndrome. ⁵³ ⁶²	Querfeld C...Kuzel TM	17367611	2007
16	CD13 and TCR clone: markers of early mycosis fungoides. ⁵³ ⁶²	Bernier C...Dreno B	17340024	2007
17	Chemokine receptor expression in cutaneous T cell and NK/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay. ⁵³ ⁶²	Yagi H...Hashizume H	16931956	2006
18	Molecular analysis of T-cell receptor beta genes in cutaneous T-cell lymphoma reveals Jbeta1 bias. ⁵³ ⁶²	Morgan SM...Smith JL	16741518	2006
19	Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases. ⁵³ ⁶²	Saeki H...Tamaki K	16859899	2006
20	CXCR3 and CCR4 double positive tumor cells in granulomatous mycosis fungoides. ⁵³ ⁶²	Shimauchi T...Tokura Y	16713487	2006
21	Immunogold detection of CD3 and CD4 antigens in patients with Mycosis fungoides. ⁵³ ⁶²	Grzanka AA...Grzanka A	17013537	2006
22	Absence of CD26 expression on skin-homing CLA+ CD4+ T lymphocytes in peripheral blood is a highly sensitive marker for early diagnosis and therapeutic monitoring of patients with Sézary syndrome. ⁵³ ⁶²	Sokolowska-Wojdylo M...Tuting T	16197392	2005
23	CCR10 is expressed in cutaneous T-cell lymphoma. ⁵³ ⁶²	Notohamiprodjo M...von Luettichau I	15700309	2005
24	Treatment with IFN-gamma increases serum levels of Th1 chemokines and decreases those of Th2 chemokines in patients with mycosis fungoides. ⁵³ ⁶²	Hino R...Tokura Y	15927812	2005
25	Concurrent mycosis fungoides and precursor B cell lymphoblastic lymphoma in a 6-year-old child. ⁵³ ⁶²	Chou YC...Hong HS	15660892	2005
26	Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy. ⁵³ ⁶²	Jones D...Medeiros LJ	15328201	2004
27	Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. ⁵³ ⁶²	Kallinich T...Kroczek RA	14708605	2003
28	Functional expression of the eotaxin receptor CCR3 in CD30+ cutaneous T-cell lymphoma. ⁵³ ⁶²	Kleinhans M...Nestle FO	12393570	2003
29	Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. ⁵³ ⁶²	Kakinuma T...Tamaki K	12522366	2003
30	Clusterin expression in malignant lymphomas: a survey of 266 cases. ⁵³ ⁶²	Saffer H...Medeiros LJ	12429802	2002
31	Relative content of cytokines in different tissues in mycosis fungoides. ⁵³ ⁶²	Savvateeva MV...Samsonov VA	12459845	2002
32	Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma. ⁵³ ⁶²	Chiarion-Sileni V...Salvagno L	12209749	2002
33	Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and sezary syndrome. ⁵³ ⁶²	Scarisbrick JJ...Whittaker SJ	11874489	2002
34	Treatment of refractory peripheral T-cell lymphoma with denileukin diftitox (ONTAK). ⁵³ ⁶²	Talpur R...Duvic M	11908715	2002
35	Cytokine profile of patients with mycosis fungoides and the immunomodulatory effect of AS101. ⁵³ ⁶²	Shohat M...David M	11720171	2001
36	Absence of T(H)2 cytokine messenger RNA expression in CD30-negative primary cutaneous large T-cell lymphomas. ⁵³ ⁶²	Vermeer MH...Willemze R	11453809	2001
37	Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. ⁵³ ⁶²	Jones D...Huh YO	11392886	2001
38	Interleukin-15 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome). ⁵³ ⁶²	Leroy S...Dreno B	11359391	2001
39	The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. ⁵³ ⁶²	Lu D...Jones D	11242798	2001
40	Gab2 is phosphorylated on tyrosine upon interleukin-2/interleukin-15 stimulation in mycosis-fungoides-derived tumor T cells and associates inducibly with SHP-2 and Stat5a. ⁵³ ⁶²	Brockdorff JL...Odum N	11340297	2001
41	Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. ⁵³ ⁶²	Duvic M	11707858	2000
42	IL-15 and IL-16 overexpression in cutaneous T-cell lymphomas: stage-dependent increase in mycosis fungoides progression. ⁵³ ⁶²	Asadullah K...Sterry W	10949545	2000
43	Expression pattern of T-cell-associated chemokine receptors and their chemokines correlates with specific subtypes of T-cell non-Hodgkin lymphoma. ⁵³ ⁶²	Jones D...Dorfman DM	10887135	2000
44	Lack of membrane expression of interleukin-2 receptor alpha chain (CD25) in mycosis fungoides: application of laser scanning cytometry for phenotyping of skin infiltrating lymphocytes. ⁵³ ⁶²	Gniadecki R	10777356	2000
45	Interferon-alpha-associated development of bullous lesions in mycosis fungoides. ⁵³ ⁶²	Pfohler C...Reinhold U	10681616	2000
46	Macrophage-derived chemokine production by activated human T cells in vitro and in vivo: preferential association with the production of type 2 cytokines. ⁵³ ⁶²	Galli G...Romagnani S	10602042	2000
47	Expression of the CD4+ cell-specific chemoattractant interleukin-16 in mycosis fungoides. ⁵³ ⁶²	Blaschke V...Neumann C	10504456	1999
48	Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells. ⁵³ ⁶²	Nielsen M...Odum N	10374878	1999
49	Human IP-9: A keratinocyte-derived high affinity CXC-chemokine ligand for the IP-10/Mig receptor (CXCR3). ⁵³ ⁶²	Tensen CP...Willemze R	10233762	1999
50	Expression of cytotoxic proteins by neoplastic T cells in mycosis fungoides increases with progression from plaque stage to tumor stage disease. ⁵³ ⁶²	Vermeer MH...Willemze R	10233858	1999

Sources

Genes for Mycosis Fungoides

Genes related to Mycosis Fungoides (3 elite genes):

(show top 50) (show all 52)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CTLA4	Cytotoxic T-Lymphocyte Associated Protein 4	Protein Coding	363.76	Gene fusion ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26258847
2	CD28	CD28 Molecule	Protein Coding	362.83	Gene fusion ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26258847
3	TNFRSF1B	TNF Receptor Superfamily Member 1B	Protein Coding	362.3	Causative somatic mutation ⁵⁸ DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)	26258847
4	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	25.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15328201 9206737
5	CD7	CD7 Molecule	Protein Coding	24.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1690762
6	CCR4	C-C Motif Chemokine Receptor 4	Protein Coding	23.33	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14708605 12393570 16713487 (more) 10887135 19239991 17975162 16197392 16931956 19242508
7	CCR10	C-C Motif Chemokine Receptor 10	Protein Coding	22.91	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	19242508 15700309
8	TIA1	TIA1 Cytotoxic Granule Associated RNA Binding Protein	Protein Coding	21.28	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10233858
9	CXCR3	C-X-C Motif Chemokine Receptor 3	Protein Coding	21.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14708605 16713487 16931956 (more) 11242798
10	IL2	Interleukin 2	Protein Coding	20.97	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11908715 12459845 17367611 (more) 7915555 2360838 9129044 11707858 1582990 11340297 11720171 20212249
11	CCL17	C-C Motif Chemokine Ligand 17	Protein Coding	20.79	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15927812 12522366 16859899
12	CCL22	C-C Motif Chemokine Ligand 22	Protein Coding	20.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10602042 15927812
13	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	20.09	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15328201 8457444 8124209 (more) 7909467 1781751 10777356 8080984 1685826 11720171
14	IFNA1	Interferon Alpha 1	Protein Coding	19.9	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10681616 7915555 9568727 (more) 19956431 7931473 7986690 1453206
15	IFNA2	Interferon Alpha 2	Protein Coding	19.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	8440560 1751352 1349233 (more) 2258637 12209749 1931709 10681616 8864634
16	DPP4	Dipeptidyl Peptidase 4	Protein Coding	19.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11392886 16197392 8541553 (more) 18089499
17	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	18.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10374878 9192639
18	CXCL9	C-X-C Motif Chemokine Ligand 9	Protein Coding	18.7	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15927812
19	ITGAE	Integrin Subunit Alpha E	Protein Coding	18.62	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7977645
20	CDKN2B	Cyclin Dependent Kinase Inhibitor 2B	Protein Coding	18.26	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11874489
21	IL5	Interleukin 5	Protein Coding	18.05	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	11453809 11720171
22	CD1A	CD1a Molecule	Protein Coding	18.03	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7593815
23	MIR155	MicroRNA 155	RNA Gene	18	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
24	IL2RB	Interleukin 2 Receptor Subunit Beta	Protein Coding	17.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	2365399 8176252 1394062
25	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	17.52	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
26	ITGAL	Integrin Subunit Alpha L	Protein Coding	16.6	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7539248 8537552
27	CLU	Clusterin	Protein Coding	16.45	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	12429802 19220628 19289586
28	TRG	T Cell Receptor Gamma Locus	Protein Coding	16.3	Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	15660892 18644018 8409516
29	CCR3	C-C Motif Chemokine Receptor 3	Protein Coding	16.29	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14708605
30	GZMB	Granzyme B	Protein Coding	16.24	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10233858
31	ITGB2	Integrin Subunit Beta 2	Protein Coding	16.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1281618 7539248
32	IL7	Interleukin 7	Protein Coding	16.04	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9017129 9129044
33	IL15	Interleukin 15	Protein Coding	16.01	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10949545 11359391 9639524
34	CXCL11	C-X-C Motif Chemokine Ligand 11	Protein Coding	15.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10233762
35	CXCL10	C-X-C Motif Chemokine Ligand 10	Protein Coding	15.8	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	9699721 15927812
36	IL16	Interleukin 16	Protein Coding	15.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	10949545 10504456
37	CCR7	C-C Motif Chemokine Receptor 7	Protein Coding	15.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	14708605
38	MIR34A	MicroRNA 34a	RNA Gene	15.44	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
39	KIR3DL2	Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 2	Protein Coding	14.7	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
40	ADA	Adenosine Deaminase	Protein Coding	14.54	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	1362831 8408919
41	MIR200C	MicroRNA 200c	RNA Gene	14.44	DISEASES inferred ¹⁴ ¹⁴ GeneCards inferred via : Publications (show sections)
42	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	14.3	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
43	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	14.17	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
44	FOXP3	Forkhead Box P3	Protein Coding	14.12	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
45	IFNG	Interferon Gamma	Protein Coding	13.87	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
46	IL4	Interleukin 4	Protein Coding	13.82	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
47	PLS3	Plastin 3	Protein Coding	13.81	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
48	BCL2	BCL2 Apoptosis Regulator	Protein Coding	13.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
49	TP53	Tumor Protein P53	Protein Coding	13.76	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
50	CD1C	CD1c Molecule	Protein Coding	13.72	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)

Sources

Variations for Mycosis Fungoides

Sources

Expression for Mycosis Fungoides

Search GEO for disease gene expression data for Mycosis Fungoides.

Sources

Pathways for Mycosis Fungoides

Pathways related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 42)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.91	CCL22 CD28 CTLA4 IFNA1 IFNA2 IL2
2	Signal Transduction ⁶⁶	13.7	TIA1 STAT3 IL2RA IL2 CXCR3 CXCL9
3	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.47	TNFRSF1B STAT3 ITGAE IL2RA IL2 IFNA2
4	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.47	CCL17 CCL22 CCR10 CCR4 CD28 CDKN2B
5	Integrin Pathway ⁶⁴ Show member pathways FAK1 Signaling ⁶⁴ GnRH Signaling ⁶⁴ Inhibition of Angiogenesis by TSP1 ⁶⁴ Transendothelial Migration of Leukocytes ⁶⁴ UPA-UPAR Pathway ⁶⁴	13.36	STAT3 ITGAE CXCR3 CXCL9 CCR4 CCR10
6	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.24	TNFRSF8 TNFRSF1B STAT3 IL2RA IL2 IFNA2
7	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.13	CCL17 CCL22 CCR10 CCR4 CD28 CXCL9
8	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.11	TNFRSF8 TNFRSF1B STAT3 IL2RA IL2 IFNA2
9	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	12.88	ITGAE IL2RA IL2 IFNA2 IFNA1
10	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.83	CCL17 CCL22 CCR10 CCR4 CXCL9 CXCR3
11	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.8	STAT3 IL2RA IL2 IFNA2 IFNA1 CXCL9
12	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	12.58	TNFRSF8 TNFRSF1B STAT3 ITGAE IL2RA IL2
13	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.56	STAT3 IL2RA IL2 IFNA2 IFNA1
14	NF-kappaB Signaling ³	12.37	TNFRSF8 TNFRSF1B STAT3 IL2RA IL2 IFNA1
15	CD28 Signaling in T-Helper Cell ⁶⁴ Show member pathways ICos-ICosL Pathway in T-Helper Cell ⁶⁴	12.21	CD28 CTLA4 IL2 IL2RA
16	Immune response Antigen presentation by MHC class II ²² Show member pathways G-protein signaling N-RAS regulation pathway ²² IL-22 Pathway ⁶⁴ Immune response IL-22 signaling pathway ²²	12.13	STAT3 IL2RA IL2 CD28
17	Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions ⁶⁵ Show member pathways Chemokine receptors bind chemokines ⁶⁶	11.98	CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
18	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.96	CD28 IFNA2 IL2 IL2RA
19	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	11.95	STAT3 IL2RA IL2
20	IL2 signaling events mediated by STAT5 ⁶¹ Show member pathways IL2 signaling events mediated by PI3K ⁶¹ IL2-mediated signaling events ⁶¹ Interleukin-2 signaling ⁶⁶	11.94	STAT3 IL2RA IL2
21	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	11.9	STAT3 IL2RA IL2
22	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.88	TNFRSF1B STAT3 CCL22
23	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.84	STAT3 IL2 CD28
24	Allograft rejection ⁷⁴	11.84	CD28 CTLA4 CXCL9 IL2 IL2RA
25	Innate Lymphoid Cells Differentiation ⁶⁵	11.73	ITGAE IL2RA IL2 CXCR3 CD7
26	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.69	ITGAE IL2 IFNA2
27	Th17 cell differentiation pathway ⁷⁴	11.66	STAT3 IL2RA IL2
28	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.64	IL2RA IL2 CTLA4
29	THC Differentiation Pathway ⁶⁴	11.51	TNFRSF1B IL2RA IL2 CD28
30	Interactions between immune cells and microRNAs in tumor microenvironment ⁷⁴	11.49	STAT3 IL2RA CTLA4
31	Interleukin-10 signaling ⁶⁶	11.47	TNFRSF1B STAT3 CCL22
32	Th2 Differentiation ⁶⁵	11.43	IL2RA IL2 CD28 CCL22 CCL17
33	IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵ Show member pathways IL-2 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.34	TNFRSF1B IL2RA IL2
34	Inflammatory response pathway ⁷⁴	11.31	TNFRSF1B IL2RA IL2 CD28
35	Prostaglandin signaling ⁷⁴	11.2	IFNA1 CXCL9 CD28
36	IL12 signaling mediated by STAT4 ⁶¹	11.19	STAT3 IL2RA IL2 CD28
37	T cell receptor and co-stimulatory signaling ⁷⁴	11.16	IL2 CTLA4 CD28
38	G-protein signaling_Rap2B regulation pathway ²²	10.96	ITGAE IL2 CXCL9 CCL22 CCL17
39	Genes associated with the development of rheumatoid arthritis ⁷⁴	10.94	IL2RA CTLA4
40	Cancer immunotherapy by CTLA4 blockade ⁷⁴	10.85	CTLA4 CD28
41	RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs) ⁶⁶	10.71	IL2RA IL2 CTLA4
42	COVID-19 adverse outcome pathway ⁷⁴	10.65	IL2RA IL2

Sources

GO Terms for Mycosis Fungoides

Cellular components related to Mycosis Fungoides according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	external side of plasma membrane	GO:0009897	9.53	ITGAE IL2RA CXCR3 CXCL9 CTLA4 CD28
2	protein complex involved in cell adhesion	GO:0098636	9.26	CTLA4 CD28

Biological processes related to Mycosis Fungoides according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	cell surface receptor signaling pathway	GO:0007166	10.16	CD28 CXCR3 IFNA2 IL2RA TNFRSF1B
2	cell-cell signaling	GO:0007267	10.16	IL2 IFNA2 CXCL9 CCL22 CCL17
3	positive regulation of cytosolic calcium ion concentration	GO:0007204	10.13	IL2 CXCR3 CCR4 CCR10
4	inflammatory response	GO:0006954	10.11	CCL17 CCL22 CCR4 CXCL9 CXCR3 IFNA2
5	humoral immune response	GO:0006959	10.04	IFNA2 IFNA1 CD28
6	T cell activation	GO:0042110	10.02	DPP4 CD7 CD28
7	chemotaxis	GO:0006935	10	CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
8	defense response	GO:0006952	9.95	STAT3 IFNA2 IFNA1 CXCL9
9	cell chemotaxis	GO:0060326	9.95	CXCR3 CCR4 CCR10 CCL22
10	positive regulation of T cell proliferation	GO:0042102	9.88	IL2RA IL2 CD28
11	activated T cell proliferation	GO:0050798	9.86	IL2RA IL2
12	regulation of T cell homeostatic proliferation	GO:0046013	9.73	IL2RA IL2
13	chemokine-mediated signaling pathway	GO:0070098	9.73	CXCR3 CXCL9 CCR4 CCR10 CCL22 CCL17
14	negative regulation of lymphocyte proliferation	GO:0050672	9.67	IL2RA IL2
15	regulation of CD4-positive, alpha-beta T cell proliferation	GO:2000561	9.67	IL2 IL2RA
16	immune response	GO:0006955	9.64	CCL17 CCL22 CCR10 CCR4 CD28 CD7
17	regulation of T cell proliferation	GO:0042129	9.62	TNFRSF1B CTLA4 CD28
18	lymphocyte proliferation	GO:0046651	9.54	IL2RA IL2

Molecular functions related to Mycosis Fungoides according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	chemokine activity	GO:0008009	9.8	CXCL9 CCL22 CCL17
2	C-C chemokine binding	GO:0019957	9.73	CXCR3 CCR4 CCR10
3	C-C chemokine receptor activity	GO:0016493	9.63	CXCR3 CCR4 CCR10
4	chemokine receptor activity	GO:0004950	9.35	CXCR3 CCR4 CCR10
5	cytokine activity	GO:0005125	9.32	IL2 IFNA2 IFNA1 CXCL9 CCL22 CCL17